Delayed puberty and peak bone mass

Bonjour, Jean‐Philippe

doi:10.1530/eje.0.1390257

Cited by 22 publications

(9 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The onset of puberty is a complex process involving the activation of the hypothalamicpituitary-gonadal axis and other endocrine systems such as the growth hormone-IGF axis of which the targets include factors influencing the bone mineral balance and the growth rate of the skeleton. Several mechanisms whereby CDGP may lead to a low peak bone mass have been suggested (130).…”

Section: Delayed Pubertymentioning

confidence: 99%

Determinants of Peak Bone Mass Acquisition

Rizzoli

Bonjour

2009

Osteoporosis

View full text Add to dashboard Cite

Section: Delayed Pubertymentioning

confidence: 99%

Determinants of Peak Bone Mass Acquisition

Rizzoli

Bonjour

2009

Osteoporosis

View full text Add to dashboard Cite

“…Osteoporosis is less common in men because on average peak bone mass is greater in men (7,8) and bone size of the radius, femoral neck, and vertebrae are greater in men (7). Men do not have a male menopause during which significant amounts of bone can be lost.…”

Section: Protection From Osteoporosis In Menmentioning

confidence: 99%

Approach to the Prostate Cancer Patient with Bone Disease

Greenspan

2008

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

Prostate cancer is the most common visceral malignancy in men. Androgen deprivation therapy (ADT) is commonly used in patients with nonmetastatic prostate cancer and is associated with significant bone loss and fractures. The greatest bone loss occurs during initiation of ADT. Men should have assessment of skeletal integrity with bone mineral density examination by dual x-ray absorptiometry of the hip and spine. Men with fragility fractures or osteoporosis by bone density should be considered for bisphosphonate therapy. Men with low bone mass may need antiresorptive therapy, depending on other risk factors. Men with a normal bone mineral density should be followed up closely with bone densitometry while on ADT. All men should receive preventive measures with calcium (1200 mg daily in divided doses), vitamin D (800-1000 IU/d), and weight-bearing exercise. Men should be evaluated for additional secondary causes of bone loss including vitamin D insufficiency. Guidelines are needed for androgen-induced bone loss screening and treatment.

show abstract

“…During puberty, the maximal acquisition of bone mineral is achieved (Finkelstein et al 1992, Bonjour 1998) via the effect of estrogen through the nuclear receptor ERa, and its modulator, ERb (Bord et al 2001, Nilsson et al 2001, Heldring et al 2007. During this critical period of growth, children suffering from CGDP have reduced bone mineral acquisition with subsequent osteopenia in adult life (Finkelstein et al 1992, Bonjour 1998; a clinical situation that will be further complicated by the use of L. During adult life, estrogen plays an important role in bone remodeling to maintain density, mineral content, and strength in both human males and females.…”

Section: Introductionmentioning

confidence: 99%

“…During this critical period of growth, children suffering from CGDP have reduced bone mineral acquisition with subsequent osteopenia in adult life (Finkelstein et al 1992, Bonjour 1998; a clinical situation that will be further complicated by the use of L. During adult life, estrogen plays an important role in bone remodeling to maintain density, mineral content, and strength in both human males and females. Clinically, when there is estrogen deficiency, as in postmenopausal women, it is associated with bone mineral loss and osteoporosis (Albright et al 1941, Riggs et al 2002.…”

Section: Introductionmentioning

confidence: 99%

“…This effect is utilized to increase the predicted adult height, in children with ISS and CGDP (MacGillivray et al 1998, Dunkel & Wickman 2001, Shulman et al 2008. CGDP is reported in literature to be associated with reduced bone mineral acquisition, and reduced bone mass in adult life (Finkelstein et al 1992, Bonjour 1998. The population of children with CGDP may utilize the L to improve the predicted adult height, and the induction of an estrogen deficienct state after the treatment may further compromise the bone mineral acquisition (Carani et al 1997, MacGillivray et al 1998, Dunkel & Wickman 2001.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats

Idris

Yeh²

2009

Journal of Endocrinology

View full text Add to dashboard Cite

Long-term aromatase inhibitor use causes bone loss and increases fracture risk secondary to induced estrogen deficiency. We postulated that alfacalcidol (A; vitamin D 3 analog) could help prevent the Letrozole (L)-induced mineral bone loss. Fifty intact 1-month-old female rats were randomly divided into basal group; age-matched control group (AMC); L group: oral administration of 2 mg/kg per day; A group: oral administration of 0 . 1 mg/kg per day; and group LCA for a period of 8 weeks. Eight-week administration of L resulted in a significant increase in body weight, bone length, bone area, bone formation, and bone resorption activities when compared with the AMC group. However, the bone mass and bone mineral density (BMD) were significantly lower than the AMC group. Serum levels of testosterone, LH, FSH, and IGF-1 were significantly higher and serum estrone and estradiol were lower along with a decrease in ovaryCuterus horn weight, when compared with the AMC groups. None of those parameters were affected by A treatment, except suppression of bone resorption activities and increased trabecular bone mass and femoral BMD, when compared with the AMC group. Results of LCA combined intervention showed that bone length, bone area, and bone formation activities were higher than the AMC group, and the bone resorption activities were lower and BMD was significantly higher than that of the L group. This study demonstrates that the combined intervention of L and A not only enhances bone growth, but also increases bone density, and the effects of L and A are independent and additive.

show abstract

Delayed puberty and peak bone mass

Cited by 22 publications

References 14 publications

Determinants of Peak Bone Mass Acquisition

Determinants of Peak Bone Mass Acquisition

Approach to the Prostate Cancer Patient with Bone Disease

Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats

Contact Info

Product

Resources

About